Trials / Completed
CompletedNCT02227173
A Phase 1 Drug-drug Interaction Study in Healthy Volunteers
Effect of BMS-986020 on the Pharmacokinetics of Montelukast, Flurbiprofen, and Digoxin as Probe Substrates for CYP2C8, CYP2C9, and P-gp
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label, single-sequence, drug-drug interaction study in healthy male and female subjects. There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-986020 with montelukast, flurbiprofen, and digoxin may increase the exposure of montelukast, flurbiprofen, and digoxin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986020 | |
| DRUG | Montelukast | |
| DRUG | Flurbiprofen | |
| DRUG | Digoxin |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2014-08-27
- Last updated
- 2014-11-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02227173. Inclusion in this directory is not an endorsement.